[1] Jabbour E,Kantarjian H.Chronic myeloid leukemia:2012 update on diagnosis,monitoring,and management [J].Am J Hematol,2012,87(11):1037-1045.[2] Dickinson AM,Pearce KF,Norden J,et al.Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia [J].Haematologica,2010,95(6):922-927.[3] Rousselot P,Charbonnier A,Cony-Makhoul P,et al.Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease [J].J Clin Oncol,2014,32(5):424-430.[4] Song P,Ye L,Fan J,et al.Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells [J].Oncotarget,2015,6(6):3861-3873.[5] Zhen YS,Xue YC,Shao RG.Antitum activity of the new enediyne antibiotic C-1027 [J].Chin J Antib,1994,19(2):164-168.[6] Chen J,Ouyang ZG,Zhang SH,et al.Down-regulation of the nuclear factor-kappa B by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth [J].Oncol Rep,2007,17(6):1445-1451.[7] Zhong GS,Guo XF,Zhang SH,et al.Optimization of the assembly efficiency for lidamycin chromophore bound to its aporotein:a case study using orthogonal array [J].Biomed Environ Sci,2011,24(6):602-607.[8] Zhen HY,He QH,Zhen YZ,et al.Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct 4,Sox 2 and Myc [J].Invest New Drugs,2011,29(6):1188-1197.[9] Zhang Q,Liu XJ,Hu L,et al.Factor Ⅶ light chain-targeted lidamycin targets tissue factor-over expressing tumor cells for cancer therapy [J].Int J Mol Med,2012,29(3):409-415.[10] Zhang SH,Zhang H,He HW,et al.Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma[J].Cancer Chemother Pharmacol,2013,72(4):777-788.[11] Deininger MW,Goldman JM,Melo JV.The molecular biology of chronic myeloid leukemia [J].Blood,2000,96(10):3343-3356.[12] von Bubnoff N,Duyster J.Chronic myelogenous leukemia treatment and monitoring [J].Dtsch Arztebl Int,2010,107(7):114-121.[13] Dziegielewski J,Beerman TA.Cellular responses to the DNA strand-scission enediyne C-1027 can be independent of ATM,ATR,and DNA-PK kinases [J].J Biol Chem,2002,277(23):20549-20554.[14] Plati J,Bucur O,Khosravi-Far R.Apoptotic cell signaling in cancer progression and therapy [J].Integr Biol (Camb),2011,3(4):279-296.[15] Mukhtar E,Adhami VM,Khan N,et al.Apoptosis and autophagy induction as mechanism of cancer prevention by naturally occurring dietary agents [J].Curr Drug Targets,2012,13(14):1831-1841.[16] Sastry KSR,Al-Muftah MA,Li P,et al.Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells [J].Cell Death Differ,2014,21(12):1936-1949.[17] Giussani P,Tringali C,Riboni L,et al.Sphingolipids:key regulators of apoptosis and pivotal players in cancer drug resistance [J].Int J Mol Sci,2014,15(3):4356-4392.[18] Chang HY,Yang X.Proteases for cell suicide:functions and regulation of caspases [J].Microbiol Mol Biol Rev,2000,64(4):821-846.[19] Zhao Y,Lei M,Wang Z,et al.TCR-induced,PKC-mediated NF-κB is regulated by a caspase-8-caspase-9-caspase-3 cascade[J].Biochem Biophys Res Commun,2014,450(1):526-531. |